The Hindu Business Line : GSK Pharma (Rs 1,179.15): Buy

We recommend a buy in GlaxoSmithKline Pharmaceuticals from a short-term horizon. It is clearly visible from the charts of GlaxoSmithKline Pharmaceuticals that it was on a long-term down trend from its April 2006 high of Rs 1,553 to its January 2008 low of Rs 704. However, the stock reversed direction in January and has been on a steady uptrend since then. We notice an inverse complex head and shoulders pattern, spanning over the past nine months with neckline at Rs 1,150. On July 8, the stock decisively broke out of the neckline by surging more than 3 per cent, accompanied with above 2 week average volume. The stock is trading well above its 21 and 50-day moving averages. The daily and weekly momentum indicators are featuring in the bullish zone. The daily moving average convergence and divergence (MACD) is featuring in the positive territory and the weekly MACD has entered this territory. Besides, the up trendline of the stock is intact. Our short-term forecast for the stock is bullish and we expect it to rally until it hits our price target of Rs 1,300 in the forthcoming trading sessions. Traders with short-term perspective can buy the stock while maintaining stop-loss at Rs 1,125.

Yoganand D.

Related Stories:
GSK Consumer Healthcare Q1 net up 34% at Rs 56 cr
GSK Pharma to bring in rotavirus, cancer vaccines

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page